Dow Strengthens Affinisol Portfolio for Drug Formulators
New polymers from Dow presented at CPhI 2014 help maximize a pharmaceutical product's solubilization performance.
Poorly soluble drug candidates can now get some help from Dow’s new polymers, which are designed to address the solubilization performance requirements of a pharmaceutical company’s APIs in spray-dried dispersion (SDD) and hot-melt extrusion (HME) formulations.
Dow’s solution for SDD is Affinisol HPMCAS (Hypromellose Acetate Succinate), a range of polymers that help maintain stable solid dispersions and inhibit API crystallization. The product offers polymer-tailoring options to maximize solubilization.
For HME formulations, Dow offers Affinisol HPMC (Hyromellose), a next-generation crystallization inhibitor that can be extruded over a wide range of temperatures without the use of plasticizers. Because of its low glass transition temperature, the product “provides drug formulators with new capabilities to formulate amorphous solid dispersions and controlled release profiles via extrusion processes,” according to a press release.
Source:
Dow
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
